Drug products: Boltin, Livial, Livial®, Tibelia, Tibocina, Tibolon Aristo, Tibolon Mylan, Tibolon Orifarm
ATC code: G03CX01
As the substance is only used by women, analyses on sex or gender differences have not been considered relevant.
Tibolone is used as hormone replacement therapy (HRT) in estrogen deficiency syndrome in women more than one year after menopause [1,2], and as second line treatment for the prevention of osteoporosis in postmenopausal women at high risk of future fractures and with intolerance to, or contraindicated for, other medical drugs approved for the prevention of osteoporosis . It is not used in the US .
Date of litterature search: 2016-12-20
- Fass.se [cited 2016-12-20]. länk
- Formoso G, Perrone E, Maltoni S, Balduzzi S, Wilkinson J, Basevi V et al. Short-term and long-term effects of tibolone in postmenopausal women. Cochrane Database Syst Rev. 2016;10:CD008536. PubMed
- Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-12-19.] Socialstyrelsens statistikdatabas
Reviewed by: Mia von Euler
Approved by: Karin Schenck-Gustafsson